US · BLFS
BioLife Solutions, Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Bothell, WA 98021
- Website
- biolifesolutions.com
Price · as of 2025-12-31
$21.21
Market cap 1.17B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $36.07 | +70.06% |
| Intrinsic Value(DCF) | $10.96 | -48.33% |
| Graham-Dodd Method(GD) | $6.52 | -69.27% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $0.00 | $0.00 | |||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $0.00 | $0.00 | |||
| 2014 | |||||
| 2015 | $0.00 | $6.57 | |||
| 2016 | $2.10 | $30.53 | $0.00 | $0.00 | $0.00 |
| 2017 | $5.60 | $144.82 | $4.43 | $0.00 | $0.00 |
| 2018 | $16.34 | $75.43 | $157.12 | $3.26 | $16.85 |
| 2019 | $13.98 | $54.98 | $229.70 | $2.11 | $0.00 |
| 2020 | $37.97 | $78.61 | $1,421.13 | $5.86 | $7.86 |
| 2021 | $22.93 | $93.35 | $0.03 | $5.49 | $0.00 |
| 2022 | $19.50 | $28.08 | $0.00 | $0.00 | $86.57 |
| 2023 | $17.36 | $27.28 | $0.00 | $0.00 | $0.00 |
| 2024 | $25.83 | $63.77 | $0.57 | $0.78 | $0.00 |
| 2025 | $22.52 | $36.07 | $1.20 | $6.52 | $0.00 |
AI valuation
Our deep-learning model estimates BioLife Solutions, Inc.'s (BLFS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $36.07
- Current price
- $21.21
- AI upside
- +70.06%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$10.96
-48.33% upside
Graham-Dodd
$6.52
-69.27% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BLFS | BioLife Solutions, Inc. | $21.21 | 1.17B | +70% | -48% | -69% | — | — | 2.89 | 11.18 | -103.07 | — | 2.89 | 64.56% | -12.61% | -12.61% | 0.00% | -4.52% | 0.00% | 0.03 | -4.48 | 5.23 | 5.23 | -1.18 | -4318.00% | 1697.00% | 28653.00% | 1.87% | 0.88 | 7.49% | 0.00% | — | 0.00% | -79.66 | 48.04 | 10.04 | 18.23 |
| ATRC | AtriCure, Inc. | $31.26 | 1.56B | +49% | -32% | -90% | — | -129.01 | 3.00 | 2.76 | 86.02 | — | 7.06 | 74.41% | -0.64% | -2.14% | -2.40% | -0.83% | -1.81% | 0.18 | -0.59 | 3.96 | 2.87 | -4.89 | -7474.00% | 1488.00% | -52900.00% | 3.27% | 0.70 | 11.67% | 0.00% | 0.00% | 3.01% | -405.42 | 28.94 | 2.61 | 5.82 |
| AZTA | Azenta, Inc. | $26.98 | 1.24B | +62% | -42% | -40% | — | -28.75 | 0.93 | 2.70 | 25.40 | — | 1.74 | 45.52% | -1.90% | -9.39% | -3.19% | -0.31% | -2.68% | 0.06 | — | 2.98 | 2.23 | -3.12 | -6052.00% | 355.00% | 21029.00% | 2.39% | 0.30 | 2.67% | 0.00% | 0.00% | 0.00% | -121.90 | 35.84 | 2.31 | 4.42 |
| ESTA | Establishment Labs Holdin… | $78.70 | 2.29B | -26% | +32% | — | — | -44.15 | 95.73 | 10.68 | -66.58 | — | 181.85 | 69.32% | -18.48% | -24.19% | -133.25% | -49.45% | -14.51% | 0.12 | -1.54 | 3.04 | 1.86 | 2.22 | -4267.00% | 2714.00% | -2314.00% | -2.53% | -0.62 | -82.02% | 0.00% | 0.00% | 9.21% | -55.92 | -38.31 | 10.34 | 4.85 |
| HROW | Harrow Health, Inc. | $54.18 | 2.01B | +502% | +346% | — | — | -49.72 | 12.48 | 4.35 | 47.49 | — | -7.40 | 75.33% | 4.42% | -8.76% | -24.97% | 4.11% | -4.99% | 3.29 | 0.39 | 2.08 | 1.79 | 8.21 | -3467.00% | 5332.00% | -5906.00% | -7.00% | -0.24 | -28.36% | 0.00% | 0.00% | 0.00% | 119.11 | -17.26 | 5.26 | 1.98 |
| KMTS | KESTRA MEDICAL TECHNOLOGI… | $23.28 | 1.36B | +67% | +283% | — | — | -6.49 | 3.60 | 12.35 | -5.57 | -4.28 | 3.60 | 40.47% | -177.85% | -190.28% | 5732.26% | 132.69% | -66.62% | 0.22 | -13.75 | 6.72 | 6.47 | 1.97 | 15147.00% | 11505.00% | 1941.00% | -13.70% | -2.04 | 126.23% | 0.22% | -1.50% | 31.39% | -5.13 | -5.39 | 9.12 | 2.34 |
| NEOG | Neogen Corporation | $11.23 | 2.44B | +204% | -82% | — | — | -1.01 | 0.53 | 1.23 | -2.01 | -0.01 | -2.73 | 47.10% | 1.05% | -122.06% | -41.88% | 0.27% | -27.33% | 0.44 | 0.13 | 3.32 | 1.62 | -0.84 | 1146322.00% | -320.00% | -3914.00% | -4.21% | 0.33 | -1.38% | 0.00% | 0.00% | 0.00% | 200.15 | -40.68 | 2.11 | 0.67 |
| NVCR | NovoCure Limited | $13.67 | 1.53B | +107% | -55% | — | — | -11.06 | 4.43 | 2.30 | -11.25 | — | 4.43 | 74.54% | -23.47% | -20.79% | -38.89% | -119.85% | -13.32% | 0.85 | — | 2.90 | 2.57 | -1.57 | -2179.00% | 828.00% | 932.00% | -5.02% | -0.22 | -58.98% | 0.00% | 0.00% | 22.09% | -8.71 | -17.70 | 2.04 | 0.52 |
| PHR | Phreesia, Inc. | $12.33 | 743.34M | +427% | +131% | — | — | -23.67 | 5.23 | 3.30 | -51.58 | — | 12.82 | 67.86% | -13.84% | -13.94% | -22.67% | -31.04% | -15.43% | 0.07 | -24.75 | 1.78 | 1.38 | 2.60 | -5936.00% | 1783.00% | -11443.00% | 0.60% | 0.28 | 4.43% | 0.00% | 0.00% | 0.00% | -22.71 | 159.09 | 3.14 | 4.70 |
| PLSE | Pulse Biosciences, Inc. | $18.73 | 1.27B | — | — | — | — | -17.46 | 15.75 | 3629.72 | -16.69 | -100.37 | 16.44 | -360.00% | -21982.57% | -20794.57% | -74.45% | -1168.13% | -63.68% | 0.09 | — | 10.53 | 10.22 | 1.02 | 1739.00% | — | 4927.00% | -4.29% | -6.83 | -826.49% | 0.00% | 0.00% | 0.00% | -15.56 | -21.99 | 3420.56 | 40.87 |
| STAA | STAAR Surgical Company | $19.90 | 982.38M | +92% | -59% | -70% | — | -44.58 | 2.27 | 2.87 | -123.99 | — | 2.28 | 76.32% | -4.02% | -6.44% | -5.16% | -6.20% | -4.05% | 0.10 | — | 5.23 | 4.41 | 18.43 | -19535.00% | -264.00% | 11338.00% | -0.85% | 0.22 | -3.77% | 0.00% | 0.00% | 0.17% | -56.24 | -92.48 | 2.26 | 5.87 |
About BioLife Solutions, Inc.
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
- CEO
- Roderick de Greef
- Employees
- 159
- Beta
- 1.92
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($10.96 ÷ $21.21) − 1 = -48.33% (DCF, example).